Arch Therapeutics (Arch Therapeutics) FCF Margin % : -2,187.50% (As of Mar. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Arch Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Arch Therapeutics's Free Cash Flow for the three months ended in Mar. 2024 was $-0.70 Mil. Arch Therapeutics's Revenue for the three months ended in Mar. 2024 was $0.03 Mil. Therefore, Arch Therapeutics's FCF Margin % for the quarter that ended in Mar. 2024 was -2,187.50%.

As of today, Arch Therapeutics's current FCF Yield % is -65.99%.

The historical rank and industry rank for Arch Therapeutics's FCF Margin % or its related term are showing as below:

ARTH' s FCF Margin % Range Over the Past 10 Years
Min: -49683.33 Med: -27850 Max: -2815.27
Current: -2815.27

During the past 13 years, the highest FCF Margin % of Arch Therapeutics was -2815.27%. The lowest was -49683.33%. And the median was -27850.00%.

ARTH's FCF Margin % is ranked worse than
84.32% of 1046 companies
in the Biotechnology industry
Industry Median: -144.01 vs ARTH: -2815.27

Arch Therapeutics FCF Margin % Historical Data

The historical data trend for Arch Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arch Therapeutics FCF Margin % Chart

Arch Therapeutics Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

FCF Margin %

Get a 7-Day Free Trial

-49,683.33

-27,850.00

-4,446.05

Arch Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-3,529.41	-6,907.69	-3,067.50	-1,876.09	-2,187.50

Competitive Comparison of Arch Therapeutics's FCF Margin %

For the Biotechnology subindustry, Arch Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arch Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arch Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Arch Therapeutics's FCF Margin % falls into.

Arch Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Arch Therapeutics's FCF Margin for the fiscal year that ended in Sep. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Sep. 2023 )	/	Revenue (A: Sep. 2023 )
	=	-3.379	/	0.076
	=	-4,446.05 %

Arch Therapeutics's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-0.7	/	0.032
	=	-2,187.50 %

Arch Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Arch Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Arch Therapeutics (Arch Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arch Therapeutics Inc (OTCPK:ARTH) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

235 Walnut Street, Suite 6, Framingham, MA, USA, 01702

Website

https://www.archtherapeutics.com

Arch Therapeutics Inc is a development-stage biotechnology company. It focuses on developing products that manage surgery and interventional care faster and safer by using a novel approach to stop bleeding, control leaking, and provide other advantages during surgery and trauma care. The company's primary product candidate, collectively known as the AC5 Devices (AC5), is designed to achieve hemostasis in surgical procedures. The company operates its business operations in the United States.

Executives

Terrence W Norchi	director, officer: President & CEO	C/O ARCH THERAPEUTICS, INC., PO BOX 748, NATICK MA 01760
Michael S Abrams	officer: CFO and Treasurer	64 RAMSHEAD ROAD, RAYNHAM MA 02767
Laurence Hicks	director	C/O ARCH THERAPEUTICS, INC., 235 WALNUT STREET, SUITE 6, FRAMINGHAM MA 01702
Guy L. Fish	director	C/O ARCH THERAPEUTICS, INC., 235 WALNUT STREET, SUITE 6, FRAMINGHAM MA 01702
Dan Yrigoyen	officer: Vice President, Sales	C/O ARCH THERAPEUTICS, INC., 235 WALNUT STREET, SUITE 6, FRAMINGHAM MA 01702
James R Sulat	director
Punit Dhillon	director	5820 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Richard E Davis	officer: CFO & Treasurer
Avtar S Dhillon	director	C/O GENETRONICS INC, 11199 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Arthur L Rosenthal	director	100 CYBERONICS BLVD., HOUSTON TX 77058
Alan Barber	officer: Chief Financial Officer	C/O ARCH THERAPEUTICS, INC., PO BOX 748, NATICK MA 01760
William M Cotter	officer: Chief Operating Officer	C/O CLOSURE MEDICAL CORP, 5250 GREEN DAIRY RD, RALEIGH NC 27616